Updated on 10 June 2016
Benagluru: Sequenom Inc, a US-based life sciences company committed to enabling healthier lives through the development of innovative products and services, has announced that it filed a patent infringement lawsuit in Australia. The patent relates to the detection of cell-free fetal DNA for non-invasive prenatal testing (NIPT).
The lawsuit was filed against Sonic Healthcare, Australian Clinical Labs and Ariosa Diagnostics, Inc. in the Australian Federal Court. The suit accuses Sonic Healthcare and Australian Clinical Labs' use of the Harmony NIPT test supplied by Ariosa of infringing Australian Patent 727,919. Sequenom is seeking all available remedies, including damages (or an account of profits) and restraint.
"Sequenom established the NIPT market with the introduction of the MaterniT 21 laboratory-developed test in 2011 and has developed pioneering intellectual property in the NIPT testing field," said Dirk van den Boom, President and CEO of Sequenom. "In 2014, we entered into an agreement with Illumina Inc to pool our NIPT intellectual property and allow for easier access to both parties' NIPT technology by healthcare providers and their patients. Currently, over 45 healthcare organizations globally have licensed the intellectual property in order to develop and deliver the highest quality NIPT tests. We are committed to preserving the value of the intellectual property of the patent pool for the benefit of our licensees, and this lawsuit adds to suits already filed in the UK and in Europe."